Home » Stocks » TLC

Taiwan Liposome Company, Ltd. (TLC)

Stock Price: $4.40 USD -0.44 (-9.05%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $4.67 +0.27 (6.14%) Jan 22, 7:55 PM
Market Cap 194.58M
Revenue (ttm) 6.95M
Net Income (ttm) -26.83M
Shares Out 64.05M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.40
Previous Close $4.84
Change ($) -0.44
Change (%) -9.05%
Day's Open 4.85
Day's Range 4.40 - 5.17
Day's Volume 76,386
52-Week Range 3.00 - 8.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 04, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines...

GlobeNewsWire - 3 weeks ago

On-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses On-schedule completion of enrollment despite COVID-19...

GlobeNewsWire - 1 month ago

Patient enrollment of EXCELLENCE pivotal trial reaches 98%

GlobeNewsWire - 2 months ago

Technology can be quickly translated and applied to other drugs for direct, extended release delivery to the lungs and is open for collaboration Technology can be quickly translated and applie...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicine...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 14, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines...

GlobeNewsWire - 3 months ago

Dual government support in streamlined development of anti-COVID-19 therapy Dual government support in streamlined development of anti-COVID-19 therapy

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedici...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 11, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedi...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedi...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedi...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 26, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedic...

24/7 Wall Street - 5 months ago

Taiwan Liposome Co. Ltd (NASDAQ: TLC) shares shot higher on Friday after the company announced it was making a regulatory filing for a COVID-19 treatment that has been at the center of some co...

GlobeNewsWire - 5 months ago

1% of oral dose for 30-fold lung exposure and reduced cardiotoxicity A cost-effective, easily accessible, user-friendly potential treatment/prevention option

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 05, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicin...

GlobeNewsWire - 6 months ago

Achieving 30x exposure in lungs at significantly lower dose while reducing systemic and cardiac toxicities Achieving 30x exposure in lungs at significantly lower dose while reducing systemic a...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 30, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedic...

Benzinga - 7 months ago

Taiwan Liposome (NASDAQ: TLC) shares are trading higher on Monday. The company announced the results of its TLCS590 Phase 2 Trial for its Postsurgical pain management demonstrated greater redu...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines ...

GlobeNewsWire - 8 months ago

Subgroup analyses of Phase II data confirm robustness of TLC599’s efficacy response of greater pain reductions than placebo through 24 weeks Subgroup analyses of Phase II data confirm robustne...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 13, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicine...

GlobeNewsWire - 8 months ago

TLC is the only listed biotech company to achieve the elite status every year TLC is the only listed biotech company to achieve the elite status every year

GlobeNewsWire - 11 months ago

Topline results on the analgesic efficacy of TLC590 for postsurgical pain management following the hard tissue surgery are expected in mid-2020 Topline results on the analgesic efficacy of TLC...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan , Jan. 08, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicine...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 27, 2019 (GLOBE NEWSWIRE) --  – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanom...

Zacks Investment Research - 1 year ago

Taiwan Liposome has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 24, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedic...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicin...

GlobeNewsWire - 1 year ago

TLC590 showed faster and longer lasting pain relief than ropivacaine TLC590 showed faster and longer lasting pain relief than ropivacaine

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 20, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the developme...

GlobeNewsWire - 1 year ago

MRI evaluation suggests slowing of cartilage damage and potential chondroprotection in osteoarthritis of the knee MRI evaluation suggests slowing of cartilage damage and potential chondroprote...

GlobeNewsWire - 1 year ago

- Phase II results showed statistically significant pain relief through 24 weeks - Phase III to evaluate efficacy of single and repeated doses up to 52 weeks

GlobeNewsWire - 1 year ago

TLC178 shows potential as a treatment for sarcomas, with enhanced efficacy, reduced toxicity and decreased dosing frequency TLC178 shows potential as a treatment for sarcomas, with enhanced ef...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to partici...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) today announced that the management team is scheduled to present at the two upc...

About TLC

Taiwan Liposome Company,, a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-enc... [Read more...]

Industry
Biotechnology
IPO Date
Nov 21, 2018
CEO
Jilong Hong
Stock Exchange
NASDAQ
Ticker Symbol
TLC
Full Company Profile

Financial Performance

In 2019, TLC's revenue was 209.14 million, an increase of 235.57% compared to the previous year's 62.32 million. Losses were -807.52 million, -10.43% less than in 2018.

Financial numbers in millions TWD.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for TLC stock is "Buy." The 12-month stock price forecast is 12.75, which is an increase of 189.77% from the latest price.

Price Target
$12.75
(189.77% upside)
Analyst Consensus: Buy